Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
microRNA-378a-5p iS a novel positive regulator of melanoma progression.

Oncogenesis

Tupone MG, D'Aguanno S, Di Martile M, Valentini E, Desideri M, Trisciuoglio D, Donzelli S, Sacconi A, Buglioni S, Ercolani C, Biagioni A, Fibbi G, Fattore L, Mancini R, Ciliberto G, Blandino G, Del Bufalo D.
PMID: 32060259
Oncogenesis. 2020 Feb 14;9(2):22. doi: 10.1038/s41389-020-0203-6.

Evaluating the expression levels of miR-378a-5p both in a large melanoma patient cohort from The Cancer Genome Atlas database and in melanoma patients from our Institute, we found that miR-378a-5p is upregulated in metastatic melanoma specimens. miR-378a-5p expression was...

Cite
Tupone MG, D'Aguanno S, Di Martile M, et al. microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis. 2020;9(2):22doi: 10.1038/s41389-020-0203-6.
Tupone, M. G., D'Aguanno, S., Di Martile, M., Valentini, E., Desideri, M., Trisciuoglio, D., Donzelli, S., Sacconi, A., Buglioni, S., Ercolani, C., Biagioni, A., Fibbi, G., Fattore, L., Mancini, R., Ciliberto, G., Blandino, G., & Del Bufalo, D. (2020). microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis, 9(2), 22. https://doi.org/10.1038/s41389-020-0203-6
Tupone, Maria Grazia, et al. "microRNA-378a-5p iS a novel positive regulator of melanoma progression." Oncogenesis vol. 9,2 (2020): 22. doi: https://doi.org/10.1038/s41389-020-0203-6
Tupone MG, D'Aguanno S, Di Martile M, Valentini E, Desideri M, Trisciuoglio D, Donzelli S, Sacconi A, Buglioni S, Ercolani C, Biagioni A, Fibbi G, Fattore L, Mancini R, Ciliberto G, Blandino G, Del Bufalo D. microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis. 2020 Feb 14;9(2):22. doi: 10.1038/s41389-020-0203-6. PMID: 32060259; PMCID: PMC7021836.
Copy Download .nbib Format: NLM
A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting γ-tubulin.

Cell division

Traversi G, Staid DS, Fiore M, Percario Z, Trisciuoglio D, Antonioletti R, Morea V, Degrassi F, Cozzi R.
PMID: 31007707
Cell Div. 2019 Apr 10;14:3. doi: 10.1186/s13008-019-0046-8. eCollection 2019.

BACKGROUND: Resveratrol and its natural stilbene-containing derivatives have been extensively investigated as potential chemotherapeutic agents. The synthetic manipulation of the stilbene scaffold has led to the generation of new analogues with improved anticancer activity and better bioavailability. In the...

Cite
Traversi G, Staid DS, Fiore M, et al. A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting γ-tubulin. Cell Div. 2019;14:3doi: 10.1186/s13008-019-0046-8.
Traversi, G., Staid, D. S., Fiore, M., Percario, Z., Trisciuoglio, D., Antonioletti, R., Morea, V., Degrassi, F., & Cozzi, R. (2019). A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting γ-tubulin. Cell division, 143. https://doi.org/10.1186/s13008-019-0046-8
Traversi, Gianandrea, et al. "A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting γ-tubulin." Cell division vol. 14 (2019): 3. doi: https://doi.org/10.1186/s13008-019-0046-8
Traversi G, Staid DS, Fiore M, Percario Z, Trisciuoglio D, Antonioletti R, Morea V, Degrassi F, Cozzi R. A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting γ-tubulin. Cell Div. 2019 Apr 10;14:3. doi: 10.1186/s13008-019-0046-8. eCollection 2019. PMID: 31007707; PMCID: PMC6457039.
Copy Download .nbib Format: NLM
Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma.

Cancers

Rea J, Carissimo A, Trisciuoglio D, Illi B, Picard D, Remke M, Laneve P, Caffarelli E.
PMID: 34359754
Cancers (Basel). 2021 Jul 30;13(15). doi: 10.3390/cancers13153853.

The impact of protein-coding genes on cancer onset and progression is a well-established paradigm in molecular oncology. Nevertheless, unveiling the contribution of the noncoding genes-including long noncoding RNAs (lncRNAs)-to tumorigenesis represents a great challenge for personalized medicine, since they...

Cite
Rea J, Carissimo A, Trisciuoglio D, et al. Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. Cancers (Basel). 2021;13(15)doi: 10.3390/cancers13153853.
Rea, J., Carissimo, A., Trisciuoglio, D., Illi, B., Picard, D., Remke, M., Laneve, P., & Caffarelli, E. (2021). Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. Cancers, 13(15), . https://doi.org/10.3390/cancers13153853
Rea, Jessica, et al. "Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma." Cancers vol. 13,15 (2021). doi: https://doi.org/10.3390/cancers13153853
Rea J, Carissimo A, Trisciuoglio D, Illi B, Picard D, Remke M, Laneve P, Caffarelli E. Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. Cancers (Basel). 2021 Jul 30;13(15). doi: 10.3390/cancers13153853. PMID: 34359754; PMCID: PMC8345409.
Copy Download .nbib Format: NLM
PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.

International journal of molecular sciences

Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A.
PMID: 34884931
Int J Mol Sci. 2021 Dec 04;22(23). doi: 10.3390/ijms222313122.

Neuroblastoma is a severe childhood disease, accounting for ~10% of all infant cancers. The amplification of the MYCN gene, coding for the N-Myc transcription factor, is an essential marker correlated with tumor progression and poor prognosis. In neuroblastoma cells,...

Cite
Boi D, Souvalidou F, Capelli D, et al. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Int J Mol Sci. 2021;22(23)doi: 10.3390/ijms222313122.
Boi, D., Souvalidou, F., Capelli, D., Polverino, F., Marini, G., Montanari, R., Pochetti, G., Tramonti, A., Contestabile, R., Trisciuoglio, D., Carpinelli, P., Ascanelli, C., Lindon, C., De Leo, A., Saviano, M., Di Santo, R., Costi, R., Guarguaglini, G., & Paiardini, A. (2021). PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. International journal of molecular sciences, 22(23), . https://doi.org/10.3390/ijms222313122
Boi, Dalila, et al. "PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc." International journal of molecular sciences vol. 22,23 (2021). doi: https://doi.org/10.3390/ijms222313122
Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Int J Mol Sci. 2021 Dec 04;22(23). doi: 10.3390/ijms222313122. PMID: 34884931.
Copy Download .nbib Format: NLM
New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy.

Drug discovery today

Trisciuoglio D, Del Bufalo D.
PMID: 33545382
Drug Discov Today. 2021 May;26(5):1126-1135. doi: 10.1016/j.drudis.2021.01.027. Epub 2021 Feb 02.

Prosurvival and antiapoptotic B cell lymphoma-2 (Bcl-2) family proteins are often overexpressed in cutaneous melanoma, one of the most aggressive types of human cancer. They are also implicated in resistance to therapy and participate in melanoma progression by regulating...

Cite
Trisciuoglio D, Del Bufalo D. New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy. Drug Discov Today. 2021;26(5):1126-1135doi: 10.1016/j.drudis.2021.01.027.
Trisciuoglio, D., & Del Bufalo, D. (2021). New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy. Drug discovery today, 26(5), 1126-1135. https://doi.org/10.1016/j.drudis.2021.01.027
Trisciuoglio, Daniela, and Del Bufalo, Donatella. "New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy." Drug discovery today vol. 26,5 (2021): 1126-1135. doi: https://doi.org/10.1016/j.drudis.2021.01.027
Trisciuoglio D, Del Bufalo D. New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy. Drug Discov Today. 2021 May;26(5):1126-1135. doi: 10.1016/j.drudis.2021.01.027. Epub 2021 Feb 02. PMID: 33545382.
Copy Download .nbib Format: NLM
Preaugmentation Soft Tissue Expansion: A Report of Four Pilot Cases.

Case reports in dentistry

Asa'ad F, Bellucci G, Ferrantino L, Trisciuoglio D, Taschieri S, Del Fabbro M.
PMID: 29850276
Case Rep Dent. 2018 Apr 19;2018:3162617. doi: 10.1155/2018/3162617. eCollection 2018.

This pilot study aimed at investigating the safety and feasibility of pre-augmentation soft tissue expansion (STE). Tissue expanders of different sizes (from 240 to 1300 mm

Cite
Asa'ad F, Bellucci G, Ferrantino L, et al. Preaugmentation Soft Tissue Expansion: A Report of Four Pilot Cases. Case Rep Dent. 2018;2018:3162617doi: 10.1155/2018/3162617.
Asa'ad, F., Bellucci, G., Ferrantino, L., Trisciuoglio, D., Taschieri, S., & Del Fabbro, M. (2018). Preaugmentation Soft Tissue Expansion: A Report of Four Pilot Cases. Case reports in dentistry, 20183162617. https://doi.org/10.1155/2018/3162617
Asa'ad, Farah, et al. "Preaugmentation Soft Tissue Expansion: A Report of Four Pilot Cases." Case reports in dentistry vol. 2018 (2018): 3162617. doi: https://doi.org/10.1155/2018/3162617
Asa'ad F, Bellucci G, Ferrantino L, Trisciuoglio D, Taschieri S, Del Fabbro M. Preaugmentation Soft Tissue Expansion: A Report of Four Pilot Cases. Case Rep Dent. 2018 Apr 19;2018:3162617. doi: 10.1155/2018/3162617. eCollection 2018. PMID: 29850276; PMCID: PMC5933028.
Copy Download .nbib Format: NLM
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.

Oncogenesis

Di Martile M, Desideri M, Tupone MG, Buglioni S, Antoniani B, Mastroiorio C, Falcioni R, Ferraresi V, Baldini N, Biagini R, Milella M, Trisciuoglio D, Del Bufalo D.
PMID: 29472530
Oncogenesis. 2018 Feb 23;7(2):20. doi: 10.1038/s41389-018-0026-x.

Sarcomas are rare tumors with generally poor prognosis, for which current therapies have shown limited efficacy. Histone deacetylase inhibitors (HDACi) are emerging anti-tumor agents; however, little is known about their effect in sarcomas. By using established and patient-derived sarcoma...

Cite
Di Martile M, Desideri M, Tupone MG, et al. Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis. 2018;7(2):20doi: 10.1038/s41389-018-0026-x.
Di Martile, M., Desideri, M., Tupone, M. G., Buglioni, S., Antoniani, B., Mastroiorio, C., Falcioni, R., Ferraresi, V., Baldini, N., Biagini, R., Milella, M., Trisciuoglio, D., & Del Bufalo, D. (2018). Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis, 7(2), 20. https://doi.org/10.1038/s41389-018-0026-x
Di Martile, Marta, et al. "Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma." Oncogenesis vol. 7,2 (2018): 20. doi: https://doi.org/10.1038/s41389-018-0026-x
Di Martile M, Desideri M, Tupone MG, Buglioni S, Antoniani B, Mastroiorio C, Falcioni R, Ferraresi V, Baldini N, Biagini R, Milella M, Trisciuoglio D, Del Bufalo D. Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis. 2018 Feb 23;7(2):20. doi: 10.1038/s41389-018-0026-x. PMID: 29472530; PMCID: PMC5833676.
Copy Download .nbib Format: NLM
Prognostic Value of Immunoglobulin G (IgG) Patterns by Western Blotting Immunodetection in Treated Dogs Previously Infected with .

Veterinary sciences

Elmahallawy EK, Zanet S, Poggi M, Alsharif KF, Lokman MS, Trisciuoglio A, Ferroglio E.
PMID: 34941820
Vet Sci. 2021 Nov 27;8(12). doi: 10.3390/vetsci8120293.

Leishmaniasis is a heterogeneous group of neglected tropical diseases with various clinical syndromes, which is caused by obligate intracellular protozoa of the genus

Cite
Elmahallawy EK, Zanet S, Poggi M, et al. Prognostic Value of Immunoglobulin G (IgG) Patterns by Western Blotting Immunodetection in Treated Dogs Previously Infected with . Vet Sci. 2021;8(12)doi: 10.3390/vetsci8120293.
Elmahallawy, E. K., Zanet, S., Poggi, M., Alsharif, K. F., Lokman, M. S., Trisciuoglio, A., & Ferroglio, E. (2021). Prognostic Value of Immunoglobulin G (IgG) Patterns by Western Blotting Immunodetection in Treated Dogs Previously Infected with . Veterinary sciences, 8(12), . https://doi.org/10.3390/vetsci8120293
Elmahallawy, Ehab Kotb, et al. "Prognostic Value of Immunoglobulin G (IgG) Patterns by Western Blotting Immunodetection in Treated Dogs Previously Infected with ." Veterinary sciences vol. 8,12 (2021). doi: https://doi.org/10.3390/vetsci8120293
Elmahallawy EK, Zanet S, Poggi M, Alsharif KF, Lokman MS, Trisciuoglio A, Ferroglio E. Prognostic Value of Immunoglobulin G (IgG) Patterns by Western Blotting Immunodetection in Treated Dogs Previously Infected with . Vet Sci. 2021 Nov 27;8(12). doi: 10.3390/vetsci8120293. PMID: 34941820.
Copy Download .nbib Format: NLM
PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.

International journal of molecular sciences

Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A.
PMID: 34884931
Int J Mol Sci. 2021 Dec 04;22(23). doi: 10.3390/ijms222313122.

Neuroblastoma is a severe childhood disease, accounting for ~10% of all infant cancers. The amplification of the MYCN gene, coding for the N-Myc transcription factor, is an essential marker correlated with tumor progression and poor prognosis. In neuroblastoma cells,...

Cite
Boi D, Souvalidou F, Capelli D, et al. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Int J Mol Sci. 2021;22(23)doi: 10.3390/ijms222313122.
Boi, D., Souvalidou, F., Capelli, D., Polverino, F., Marini, G., Montanari, R., Pochetti, G., Tramonti, A., Contestabile, R., Trisciuoglio, D., Carpinelli, P., Ascanelli, C., Lindon, C., De Leo, A., Saviano, M., Di Santo, R., Costi, R., Guarguaglini, G., & Paiardini, A. (2021). PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. International journal of molecular sciences, 22(23), . https://doi.org/10.3390/ijms222313122
Boi, Dalila, et al. "PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc." International journal of molecular sciences vol. 22,23 (2021). doi: https://doi.org/10.3390/ijms222313122
Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Int J Mol Sci. 2021 Dec 04;22(23). doi: 10.3390/ijms222313122. PMID: 34884931; PMCID: PMC8658095.
Copy Download .nbib Format: NLM
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.

Journal of medicinal chemistry

Nowak RP, Tumber A, Hendrix E, Ansari MSZ, Sabatino M, Antonini L, Andrijes R, Salah E, Mautone N, Pellegrini FR, Simelis K, Kawamura A, Johansson C, Passeri D, Pellicciari R, Ciogli A, Del Bufalo D, Ragno R, Coleman ML, Trisciuoglio D, Mai A, Oppermann U, Schofield CJ, Rotili D.
PMID: 34843649
J Med Chem. 2021 Dec 09;64(23):17031-17050. doi: 10.1021/acs.jmedchem.1c00605. Epub 2021 Nov 29.

MINA53 is a JmjC domain 2-oxoglutarate-dependent oxygenase that catalyzes ribosomal hydroxylation and is a target of the oncogenic transcription factor

Cite
Nowak RP, Tumber A, Hendrix E, et al. First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. J Med Chem. 2021;64(23):17031-17050doi: 10.1021/acs.jmedchem.1c00605.
Nowak, R. P., Tumber, A., Hendrix, E., Ansari, M. S. Z., Sabatino, M., Antonini, L., Andrijes, R., Salah, E., Mautone, N., Pellegrini, F. R., Simelis, K., Kawamura, A., Johansson, C., Passeri, D., Pellicciari, R., Ciogli, A., Del Bufalo, D., Ragno, R., Coleman, M. L., Trisciuoglio, D., Mai, A., Oppermann, U., Schofield, C. J., & Rotili, D. (2021). First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. Journal of medicinal chemistry, 64(23), 17031-17050. https://doi.org/10.1021/acs.jmedchem.1c00605
Nowak, Radosław P, et al. "First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53." Journal of medicinal chemistry vol. 64,23 (2021): 17031-17050. doi: https://doi.org/10.1021/acs.jmedchem.1c00605
Nowak RP, Tumber A, Hendrix E, Ansari MSZ, Sabatino M, Antonini L, Andrijes R, Salah E, Mautone N, Pellegrini FR, Simelis K, Kawamura A, Johansson C, Passeri D, Pellicciari R, Ciogli A, Del Bufalo D, Ragno R, Coleman ML, Trisciuoglio D, Mai A, Oppermann U, Schofield CJ, Rotili D. First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. J Med Chem. 2021 Dec 09;64(23):17031-17050. doi: 10.1021/acs.jmedchem.1c00605. Epub 2021 Nov 29. PMID: 34843649; PMCID: PMC8667043.
Copy Download .nbib Format: NLM
The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer.

Cancers

Trisciuoglio D, Degrassi F.
PMID: 35008169
Cancers (Basel). 2021 Dec 21;14(1). doi: 10.3390/cancers14010006.

Microtubules are key components of the cytoskeleton of eukaryotic cells. Microtubule dynamic instability together with the "tubulin code" generated by the choice of different α- and β- tubulin isoforms and tubulin post-translational modifications have essential roles in the control...

Cite
Trisciuoglio D, Degrassi F. The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010006.
Trisciuoglio, D., & Degrassi, F. (2021). The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer. Cancers, 14(1), . https://doi.org/10.3390/cancers14010006
Trisciuoglio, Daniela, and Degrassi, Francesca. "The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010006
Trisciuoglio D, Degrassi F. The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer. Cancers (Basel). 2021 Dec 21;14(1). doi: 10.3390/cancers14010006. PMID: 35008169; PMCID: PMC8750717.
Copy Download .nbib Format: NLM
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.

Journal of medicinal chemistry

Nowak RP, Tumber A, Hendrix E, Ansari MSZ, Sabatino M, Antonini L, Andrijes R, Salah E, Mautone N, Pellegrini FR, Simelis K, Kawamura A, Johansson C, Passeri D, Pellicciari R, Ciogli A, Del Bufalo D, Ragno R, Coleman ML, Trisciuoglio D, Mai A, Oppermann U, Schofield CJ, Rotili D.
PMID: 34843649
J Med Chem. 2021 Dec 09;64(23):17031-17050. doi: 10.1021/acs.jmedchem.1c00605. Epub 2021 Nov 29.

MINA53 is a JmjC domain 2-oxoglutarate-dependent oxygenase that catalyzes ribosomal hydroxylation and is a target of the oncogenic transcription factor

Cite
Nowak RP, Tumber A, Hendrix E, et al. First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. J Med Chem. 2021;64(23):17031-17050doi: 10.1021/acs.jmedchem.1c00605.
Nowak, R. P., Tumber, A., Hendrix, E., Ansari, M. S. Z., Sabatino, M., Antonini, L., Andrijes, R., Salah, E., Mautone, N., Pellegrini, F. R., Simelis, K., Kawamura, A., Johansson, C., Passeri, D., Pellicciari, R., Ciogli, A., Del Bufalo, D., Ragno, R., Coleman, M. L., Trisciuoglio, D., Mai, A., Oppermann, U., Schofield, C. J., & Rotili, D. (2021). First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. Journal of medicinal chemistry, 64(23), 17031-17050. https://doi.org/10.1021/acs.jmedchem.1c00605
Nowak, Radosław P, et al. "First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53." Journal of medicinal chemistry vol. 64,23 (2021): 17031-17050. doi: https://doi.org/10.1021/acs.jmedchem.1c00605
Nowak RP, Tumber A, Hendrix E, Ansari MSZ, Sabatino M, Antonini L, Andrijes R, Salah E, Mautone N, Pellegrini FR, Simelis K, Kawamura A, Johansson C, Passeri D, Pellicciari R, Ciogli A, Del Bufalo D, Ragno R, Coleman ML, Trisciuoglio D, Mai A, Oppermann U, Schofield CJ, Rotili D. First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. J Med Chem. 2021 Dec 09;64(23):17031-17050. doi: 10.1021/acs.jmedchem.1c00605. Epub 2021 Nov 29. PMID: 34843649; PMCID: PMC8667043.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries